Wird geladen...
Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea and vomiting (CINV)
Rolapitant is a highly selective neurokinin-1 receptor antagonist, orally administered for a single dose of 180 mg before chemotherapy with granisetron D1, dexamethasone 8 mg BID on day 2–4. It has a unique pharmacological characteristic of a long plasma half-life (between 163 and 183 hours); this l...
Gespeichert in:
| Veröffentlicht in: | Drug Des Devel Ther |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Dove Medical Press
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5373840/ https://ncbi.nlm.nih.gov/pubmed/28392676 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S108872 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|